Response to the letter to the editor: anticoagulant activity of bivalirudin

Marc LaineDepartment of Cardiology, Intensive care unit, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France;Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France;Centre for Cardiovascular and Nutrition research (C2VN), Marseille, FranceCorrespondence[email protected]
View further author information

Franck PaganelliDepartment of Cardiology, Intensive care unit, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France;Centre for Cardiovascular and Nutrition research (C2VN), Marseille, FranceView further author information

Laurent BonelloDepartment of Cardiology, Intensive care unit, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France;Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France;Centre for Cardiovascular and Nutrition research (C2VN), Marseille, FranceView further author information

References

Li W, Mai L, Cai X, et al. Bivalirudin infusion in patients with acute coronary syndrome after stenting. Expert Opin Pharmacother. 2019. DOI:10.1080/14656566.2019.1615329. [Epub ahead of print]
Web of Science ®Google Scholar
Laine M, Lemesle G, Dabry T, et al. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. Expert Opin Pharmacother. 2019;20:295–304.
PubMed Web of Science ®Google Scholar
Frere C, Laine M, Lemesle G, et al. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. Platelets. 2019;30:105–111.
PubMed Web of Science ®Google Scholar
Laine M, Frere C, Cuisset T, et al. Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. Int J Cardiol. 2016;220:496–500.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Response to the letter to the editor: anticoagulant activity of bivalirudin

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Response to the letter to the editor: anticoagulant activity of bivalirudin

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date